PD-L1 expression on NSCLC tumor surfaces has been used as a predictive biomarker for anti-PD-L1/PD-1 immunotherapy, and PD-L1-positive NSCLC is correlated with a higher response to anti-PD-L1/PD-1 immunotherapy [15,19]. This evidence concerns the gene CD274 and neoplasm.